

Special Issue

The Molecular Biology of Cholangiocarcinoma

Message from the Guest Editors

Our understanding of the molecular biology of cancer of the bile duct, or cholangiocarcinoma (CCA), has advanced rapidly over the last 10–15 years. Molecular profiling has identified mutations that are prevalent in different CCA sub-types, including IDH1/2 mutations and FGFR2 rearrangements, and these allow some patients to receive targeted treatment. Analysis of the CCA tumour microenvironment (TME) has also been transformed by the application of new approaches including multiplex spatial analysis of gene and protein expression and single-cell sequencing. However, important issues remain, such as the lack of proven routes to early detection, the lack of freely accessible large-scale data sets, and patchy, or non-existent, patient access to molecular profiling. We welcome primary research papers and reviews that focus on the cell and the molecular biology underlying these areas and related topics in cholangiocarcinoma research, and that thereby help to identify and close gaps in our knowledge of this disease.

Guest Editors

Prof. Dr. Kevin Gaston

Biodiscovery Institute, School of Medicine, University of Nottingham,
Nottingham NG7 2RD, UK

Prof. Dr. Padma-Sheela Jayaraman

Biodiscovery Institute, School of Medicine, University of Nottingham,
Nottingham NG7 2RD, UK

Deadline for manuscript submissions

31 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/254708

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)